July 09, 2026 02:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over' | 'It's over': Trump says on ceasefire with Iran | PM Modi visits 1,000-year-old Prambanan Temple in Indonesia, shares majestic aerial view of the holy site | Baruipur minor rape-murder case: Key accused Pravash Mondal killed in encounter | 'We have been cheated': Egypt coach slams refereeing after Argentina match sparks controversy | From 0-2 to victory! Argentina stage miraculous comeback amid referee drama to crush Egypt's World Cup dream | Amid outrage over Baruipur, another minor girl allegedly raped in West Bengal | Kerala rain fury: 2 dead, 10 feared trapped as massive Wayanad landslide triggers rescue race | Rick Scott revives Bin Laden issue, questions Pakistan's credibility as Iran mediator | Mbappé vs Paraguayan Senator: Ugly World Cup spat spirals into international controversy
COVID19
Pixabay

Portuguese researchers now discover potential drug combo against COVID-19

| @indiablooms | Aug 25, 2021, at 02:34 pm

Lisbon/UNI/Xinhua: A research team in Portugal has found three existing drugs that can help inhibit COVID-19 effects, the Diario de Noticias of Portugal daily reported Tuesday.

During the pre-clinical research, the team from the Institute of Chemical and Biological Technology of NOVA University Lisbon discovered that the drug combination can reduce the replication of SARS-CoV-2, the virus causes COVID-19, by half, said the report.

"With the drugs, we had identified that the virus only replicated at 50 percent," said Cecilia Arraiano, who leads the team, noting that the synergy could act on the Nsp14, a viral protein responsible for replication, to dampen virus activity.

The drugs could be a potential treatment that helps reduce COVID-19 hospitalization rate, according to the team.

Two of the drugs are over-the-counter medicines for treating other diseases, and the third one is pending market approval, researchers said, without disclosing drug names due to patent concern.

Arraiano said it took them nine months to have a pre-clinical discovery, and now she hopes to have more financial support to push it forward.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.